96 results
Page 3 of 5
8-K
EX-3.3
i4nohj 1w
20 Jan 21
Departure of Directors or Certain Officers
8:01am
8-K
rlwwisxh1
20 Jan 21
Departure of Directors or Certain Officers
8:01am
8-K
EX-10.1
kahyl5ya
20 Jan 21
Departure of Directors or Certain Officers
8:01am
424B5
x9bn3
23 Dec 20
Prospectus supplement for primary offering
5:05pm
8-K
EX-10.1
gdq44
9 Dec 20
Other Events
9:03am
PRER14A
4o3my 0q3
8 Dec 20
Preliminary revised proxy
4:11pm
S-8
EX-99.1
klkes03j ki50b
24 Nov 20
Registration of securities for employees
8:26am
8-K
EX-2.1
2fgzrkra y95c3c
28 Oct 20
Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for Company plans to use private placement financing proceeds of $91 million to advance multiple
9:28am
8-K
EX-10.3
9kkkcesml
17 Sep 20
Lee Rauch appointed President and CEO, following resignation by William Marshall
5:24pm
8-K
EX-10.2
mik8rat0sr4hi1c
17 Sep 20
Lee Rauch appointed President and CEO, following resignation by William Marshall
5:24pm
8-K
dnxtpa
17 Sep 20
Lee Rauch appointed President and CEO, following resignation by William Marshall
5:24pm